drugset

drugset / Trial / NCT00863538

Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

NCT00863538 ↗

Phase 2 Completed 40 enrolled Kissei Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy, safety and pharmacokinetics profile of KPS-0373 in patients with SCD

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rovatirelin	Small molecule	—	—

Indications